New York University, School of Medicine, New York, NY, USA.
New York Presbyterian - Weill Cornell Medical College, New York, NY, USA.
Cancer Chemother Pharmacol. 2019 Aug;84(2):281-285. doi: 10.1007/s00280-019-03838-x. Epub 2019 Apr 12.
Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is a treatment strategy for ovarian cancer patients with unresectable disease or poor performance status (PS). This strategy has been used in the treatment of advanced endometrial cancer and a survival benefit has been shown in patients who are subsequently able to undergo interval cytoreduction. This study sought to review our single institution experience with NACT for advanced endometrial cancer.
We conducted a retrospective review of all patients who received NACT for advanced endometrial cancer at two institutions in New York City between 2002 and 2016.
We identified 39 patients (median age 61, range 35-89). The histologic subtype distribution was: serous (44%), endometrioid (28%), carcinosarcoma (10%), clear cell (8%), mixed (8%), neuroendocrine (3%). Contraindications to primary surgery included: unresectable disease (72%), poor PS (15%), unresectable disease and poor PS (13%). Twenty-three patients (59%) did not undergo IDS due to: progression of disease (70%), medical ineligibility (4%), unresectable disease (17%), lost to follow-up (4%), death (4%). Sixteen patients (41%) underwent IDS, 81% had an optimal cytoreduction. Disease status at NACT completion was: partial response (56%), stable disease (3%) and progression of disease (41%). There were no complete responses. Patients who responded to NACT had a significantly longer overall survival than those who did not (15 vs. 5 months. P = 0.015). IDS was also associated with an improvement in overall survival versus no surgery (16 vs. 6 months, P = 0.04).
Unlike ovarian cancer, less than half of the patients undergoing NACT for endometrial cancer underwent IDS, none had a complete response, and 41% had disease progression during NACT. However, endometrial cancer patients who underwent IDS had a high rate of optimal cytoreduction. Both response to NACT and IDS were associated with improved survival.
新辅助化疗(NACT)后行间隔减瘤术(IDS)是治疗无法切除或一般状况不佳(PS)的卵巢癌患者的一种策略。这种策略已被用于治疗晚期子宫内膜癌,并在能够进行间隔减瘤术的患者中显示出生存获益。本研究旨在回顾我们单机构对晚期子宫内膜癌 NACT 的治疗经验。
我们对 2002 年至 2016 年期间在纽约市的两个机构接受 NACT 治疗的所有晚期子宫内膜癌患者进行了回顾性分析。
我们共纳入 39 例患者(中位年龄 61 岁,范围 35-89 岁)。组织学亚型分布为:浆液性(44%)、子宫内膜样(28%)、癌肉瘤(10%)、透明细胞(8%)、混合性(8%)、神经内分泌(3%)。不能行初始手术的原因包括:疾病无法切除(72%)、PS 不佳(15%)、疾病无法切除和 PS 不佳(13%)。由于疾病进展(70%)、医疗条件不适合(4%)、疾病无法切除(17%)、失访(4%)、死亡(4%),23 例患者(59%)未行 IDS。16 例患者(41%)行 IDS,81%获得最佳减瘤。NACT 完成时疾病状态为:部分缓解(56%)、稳定疾病(3%)和疾病进展(41%)。无完全缓解。对 NACT 有反应的患者的总生存时间显著长于无反应者(15 个月 vs. 5 个月,P=0.015)。与无手术相比,IDS 也与总生存改善相关(16 个月 vs. 6 个月,P=0.04)。
与卵巢癌不同,接受 NACT 治疗的子宫内膜癌患者中,不到一半的患者接受了 IDS,没有完全缓解,且 41%的患者在 NACT 期间出现疾病进展。然而,接受 IDS 的子宫内膜癌患者具有很高的最佳减瘤率。对 NACT 的反应和 IDS 均与生存改善相关。